Remedy Meds key facts
as of Oct 2026- Provider of a telehealth service intended to facilitate weight loss.
- Remedy Meds is valued at approximately $30.9M as of Oct 2026 (last reported valuation).
- It has raised $2.9M; the latest was Seed Round ($2.9M) in Nov 2025.
- Notable investors include HealthQuest Capital, Gurtin Ventures, Dynamism Capital.
- Status: Privately Held (backing).
Remedy Meds's last reported valuation, Nov 2025. Nothing priced has surfaced since.
- ·Watch Remedy Meds: the Monday email on marks, rounds and moves
Remedy Meds funding rounds
No funding rounds for Remedy Meds are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Remedy Meds
3Remedy Meds valuation
Remedy Meds's last reported valuation was $30.9 million in Nov 2025. No priced round, secondary trade or fund mark has surfaced since.
Remedy Meds investors
3 investors are on record for Remedy Meds, including HealthQuest Capital, Gurtin Ventures and Dynamism Capital.
About Remedy Meds
Provider of a telehealth service intended to facilitate weight loss. The company offers a platform that connects individuals with partner clinicians for prescriptions, provides unlimited telehealth visits, ensures access to compounded glucagon-like peptide medications from pharmacies without insurance requirements or waitlists, and offers ongoing clinical support, enabling patients to receive weight loss treatment conveniently and transparently.
- Sector
- Healthcare
- HQ
- Short Hills, NJ, United States
- Founded
- 2024
- Website
- remedymeds.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.